Evaluation of Factors That Increase the Risk of Hepatotoxicity in Patients Using Palbociclib and Ribociclib

Aim: In patients with hormone receptor-positive and HER2-negative metastatic breast cancer, the use of CDK 4/6 inhibitors in combination endocrine therapy have become a standard care.
 Methods: This was retrospective study involved over age 18 years, who had de novo or locally cancer progressed to stage were treated ribociclib and/or palbociclib.
 Results: The mean total 73 included 57.0±10.3 years. Thirty-four (46.6%) palbociclib, 35 (47.9%) ribociclib, 4 (5.5%) palbociclib ribociclib. Twenty-five (34.2%) developed any grade hepatotoxicity, 12 (16.4%) them 2 hepatotoxicity. Of these patients, 11 (44%) received 13 (52%) 1 (4%) (2.9%) 3 hepatotoxicity those (8.5%)
 (5.7%) hepatotoxicity.
 Conclusions: conclusion, it can be stated that is more toxic liver than since 3-4 no disease facilitates We believe comprehensive studies are needed determine factors facilitate such as metastasis select drug accordingly will prevent from being devoid this group drugs discontinuing their treatment due toxicity.